INTUITIVE SURGICAL INC

Intuitive Surgical insider trades reveal a cautious optimism: VP of Corporate Control buys low, sells high while liquidating options, signaling confidence yet risk‑minded strategy.

Mark Brosius’s latest insider sales signal cautious confidence in Intuitive Surgical—learn what it means for investors and the stock’s future.

Intuitive Surgical insider Mark Brosius sells 154 shares under a 10b5‑1 plan—routine trades, not a panic. Stock stays high‑valuation, long‑term growth focus.

Intuitive Surgical insider sale reveals investor confidence amid FDA scrutiny, competitive pressure, and AI‑driven growth opportunities in robotic surgery.

Intuitive Surgical insider sales by Amy Ladd are plan‑based, near‑market trades—no distress signal, just disciplined portfolio management.

Insightful analysis of Gary Loeb’s 400‑share sale at Intuitive Surgical: why the move matters for investors and what it signals about the company’s future.

CEO Rosa David J’s insider trade shows strong confidence in Intuitive Surgical’s earnings—insider buying, RSU vesting, and a positive outlook.

Intuitive Surgical insider trading shows a strategic buy‑sell balance, with executives buying at $77 and selling at $420—indicating confidence and liquidity planning.

Intuitive Surgical insider buys 531 shares—signaling confidence amid a low 52‑week price, rising social buzz, and potential market rebound.

Insider buys at Intuitive Surgical signal cautious optimism—531 shares for $457 each amid a 13.6% YTD drop, showing exec confidence in long‑term robotics growth.